ChompChompChompin Profits!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEO Urbanski brings that solid Pfizer connection in his resume.
CEO Dr. Urbanski brings that Pfizer link with his resume. It seems Pfizer would indeed be a good candidate for the mystery testing partner on the collaborative OXS 1550 trials and hopefully $GTBP is a buyout target for them, speculatively speaking at least:
Solid little awareness piece for $GTBP": GT Biopharma (OTCQB:GTBP)
This immuno-oncology biotechnology company is focused on innovative treatments based on the company's proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) as well as bispecific antibody-drug conjugate (NYSE:ADC) platforms. Recent developments for the company have seen much of the focus surrounding the company’s management team.
In fact, the last announcement from GT Biopharma included the company promoting its Chief Medical Officer, Dr. Raymond Urbanski to Chief Executive Officer and Chairman of the Board of the company. This move could prove beneficial for GT Biopharma due to the amassed experience that Dr. Urbanski has significant experience in overseeing emerging stage biotechnology companies during his time within the public sector.
Chart
GTBP Price data by YCharts
"The platform technologies that GT Biopharma has put together from the University of Minnesota has had a major impact on me coming on board. To me, it represented cutting-edge science," said Dr. Urbanski in a GT Biopharma release.
Prior to joining GT Biopharma, Dr. Urbanski spent eight years with Pfizer (NYSE:PF); holding several positions of increasing responsibility with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products, and medical director of diversified products.
Yes exactly. And welcome to the board. Here's a good place to start DD if you are just begining: https://www.gtbiopharma.com/
Now way to know yet. But I think they are being so hush hush about the identity because these kinds of buyout scenarios are usually ironclad with NDA's until its all settled.
OXS 1550 is being tested alongside a successful oncology therapy for a hitherto unnamed multibillion dollar biopharma. I smell a possible buyout deal coming!
OXS 1550 showing succes in early human trials with relapsed lymphoma and leukemia. Thats massive for GTBP.
Good to see $GTBP taking care of cash flow while keeping the cap structure under control.
NEWS! GT Biopharma Announces Completion of $5.1 Million Convertible Debt Financing
ACCESSWIRE ACCESSWIRE•August 7, 2018
LOS ANGELES, CA / ACCESSWIRE / August 7, 2018 / GT Biopharma Inc. (OTCQB: GTBP; Euronext Paris: GTBP) an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms, today announced that on August 2, 2018 it completed a private placement of convertible debentures for gross proceeds of $5,140,000.
''It is a testament to the potential of our immuno-oncology platforms and the promise for patients that our well informed and successful financing partners continue to support GT Biopharma as we move this company to the next level. Meeting our capital requirements is just one of many critical steps to advancing our drug development programs,'' said Dr. Raymond W. Urbanski, Chairman and Chief Executive Officer of GT Biopharma.
The interest rate on the convertible debentures is 10%. The convertible debentures are convertible into the Company's common stock, par value $0.001 per share, at an initial exercise price of $2 per share, subject to adjustment. The convertible debentures mature after one year.
About GT Biopharma, Inc.: GT Biopharma, Inc. is a biotechnology company focused on innovative drugs for the treatment of cancer. GT's most advanced oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific recombinant fusion protein-drug conjugate targeting CD19 and CD22 on lymphoma and leukemia cells with a modified form of diphtheria toxin as its cytotoxic dru payload. OXS-1550 targets cancer cells expressing the CD19 receptor or the CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. In addition, GTs TriKE platform will address a number of cancer types. The TriKE and TetraKE product candidates are single-chain, tri- and tetra-specific scFv recombinant fusion proteins composed of the variable regions of the heavy and light chains (or heavy chain only) of anti-CD16 antibodies, wild-type or a modified form of IL-15 and the variable regions of the heavy and light chains of an antibody designed to precisely target a specific tumor antigen. We utilize the NK stimulating cytokine human IL-15 as a crosslinker between the two scFvs which is designed to provide a self-sustaining signal leading to the proliferation and activation of NK cells thus enhancing their ability to kill cancer cells mediated by antibody-dependent cell-mediated cytotoxicity (ADCC).
IMTV looks to be heading to a penny with a bullet as we move closer to these next 2 concerts.
Seems like thats more than the lions share for LiveNation. This industry seems ripe for a shakeup.
Strong green close. This will keep inching up as we get closer to the September concert.
We would be in a sweet position for the long anticipated uplisting to NASDAQ then IMO.
The new TriKE therapies are like nothing the oncology market has ever seen. $GTBP is extraordinary!
Thats what I'm talking about bro! Buyout is looking more and more likely IMHO! Let the dollars flow!
GTBP immuno oncology pipeline is worth a fortune when the buyout offers start coming in.
OXS 1550 collobative testing could be the lead in to some BIG buyout news IMHO.
Thats a major factor in my evaluation of $IMTV. That and the cleaned up capital structure.
Haha, yeah those posts are good for laugh. $IMTV has all the indicators that breakouts coming soon.
Ha if you took a modest position and IMTV makes it up to LiveNations level you could retire comfortably.
$IMTV realy could become the next LiveNation.
Thats a great observation.
$IMTV, September in Miami, is that rainy season? Next concert is not likely to be an outdoor festival I think.
I definitely expect IMTV to push deeper into the Hip Hop space and leverage this succesful partnership with Nine Mile. But I also hope that they will continue to diversify to avoid getting typecast.
Great Corportate Update: https://finance.yahoo.com/news/imagination-tv-inc-issues-corporate-005700403.html
You still talking to that guy? Its obvious the game he's playing. I'm about to just block him. No time for fake news. $IMTV about to disappoint all the shorts.
Tekashi69 has had something like 6 number 1 hits in a row now. Itwas massive that he headlined the LIT UP Festival with $IMTV
$GTBP ought to have a very strong summer and fall. Lots of big reveals should be coming downstream here.
GTBP looks good going into next week. Watch this at open.
Good summary here: Immuno-oncology has emerged as a leading approach to address cancer over the last decade. New classes of drugs such as checkpoint inhibitors, CAR-T, oncolytic viruses and cancer vaccines have helped the body’s immune system precisely target cancer, and may replace the harsh treatments of yesteryear. New immunotherapies are advancing through clinical trials at a rapid clip including GT Biopharma’s TriKE and ADC candidates. The low cost and off the shelf availability of GT’s offerings may even displace other options such as CAR-T. While CAR-T has shown surprising efficacy, the cost is prohibitive and it only works in a minority of patients. This gap in treatment has highlighted the need for new immunotherapies and GT Biopharma’s NK cell engagers and ADCs may improve the stature of the cancer therapy formulary. The company has four immuno-oncology candidates that are in preclinical and Phase II studies. Based on company announcements and clinicaltrial.gov data, a Phase I/II trial for the TriKE platform’s OXS-1550 should begin in 2H:18. The lead program, OXS-3550 recently provided an interim update for its Phase II study showing durable responses for patients that did not benefit from prior therapy. The next stage for GT will likely be including their candidates in combination therapy where synergistic effects are expected to increase success rates. It is likely that at some point GT Biopharma will add checkpoint inhibitors or chemotherapy to a combination study. Right now, the company is focused on launching its in-man trials for OXS-3550 and completing its Phase II trial for OXS-1550. With the possibility of similar efficacy and improved safety relative to higher cost CAR-T therapy, we believe GT Biopharma merits a closer look.
The follow up to that was also strong:
GTBP Company Strategy is very impressive:
Slow and steady wins the rise. That support level is inching up.
With 7 of 13 showing a clinical benefit from OXS 1550 I wouldn't be surprised if we get a buyout offer anytime now.
Digesting the latest 8K filing: https://www.otcmarkets.com/filing/html?id=12892908&guid=SJ1EUnRCUJS4V3h
Latest OXS 1550 Phase II trial results show 7 of 13 patients demonstrated a clinical benefit!
2.05 looks like our support level is inching up for $GTBP
$GTBP hanging tough on that $2 support.
Nine Mile partnership is all about great exposure for $IMTV: "About Nine Mile Entertainment, Inc.
Nine Mile Entertainment is owned and operated by Richard Booker, Bob Marley's Brother. The company is responsible for organizing/producing the annual 9 Mile Music Festival and Food Drive in Miami, FL. More than a concert, more than a day, the 9 Mile Music Festival has provided over 4 million canned goods to various charities since its inception, distributing them to homeless shelters and food banks throughout Miami and Jamaica. The festival serves a double purpose, feeding families in need and bringing to Miami the magic and music of Jamaica and the rest of the Caribbean."